Diagnosis and treatment of renal cell carcinoma associated with von Hippel-Lindau disease
10.3760/cma.j.issn.1000-6702.2009.02.006
- VernacularTitle:von Hippel-Lindau病肾癌的诊治特点分析
- Author:
Jin ZHANG
;
Yiran HUANG
;
Dongming LIU
;
Lixin ZHOU
;
Wei XUE
;
Qi CHEN
;
Baijun DONG
;
Jiahua PAN
;
Hanqing XUAN
- Publication Type:Journal Article
- Keywords:
yon Hippel-Lindau disease;
Kidney neoplasms;
Surgical procedures,elective
- From:
Chinese Journal of Urology
2009;30(2):90-93
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the management of renal cell carcinoma(RCC) associated with von Hippel-Lindau(VHL) disease. Methods Clinical data were analyzed retrospectively from 28 ca-ses ( 16 males and 12 females, with a mean age of 45 years), of whom 15 had bilateral RCC and 13 had unilateral RCC. VHL germline mutation was analyzed in 25 cases. Nephron sparing surgery (NSS) or radical nephrectomy was performed in 24 cases. Results VHL germline mutations were detected in 25 cases including 14 asymptomatic patients. Among 29 solid renal tumors in 9 cases observed for a mean time of 44 months (range 12 to 86), the mean increase in tumor size was 0. 531 cm/year. There were 19(65.5%) tumors>3 cm at the end of follow-up but only 1 developed retroperitoneum lymph nodes metastasis. A total of 87 solid tumors were removed and 62 (71.3%) solid tumors were man-aged by NSS. Pathological results showed 86 clear cell carcinomas (73 Fuhrman Ⅰ and 12 Fuhrman Ⅱ ) and 1 calcified lesion. During mean follow-up of 50(5-237) months, local recurrence occurred in 4 cases treated with NSS; 26 patients were alive at the end of follow-up. Conclusions DNA testing might be helpful in the earlier detection of asymptomatic VHL patients. Most solid renal tumors in VHL disease grow slowly. The majority of the tumors >3 cm may still be indolent and do not metas-tasize during longer follow-up and can be observed. NSS is effective and safe for RCC in VHL disease.
